BioSpace News Archive

IBM Digital Health Pass and Salesforce Work.com to help businesses, schools and governments as they strive to reopen safely in the wake of the COVID-19 pandemic

Erasca, a company whose mission is to erase cancer, announced the appointment of Michael Varney, Ph.D., to its board of directors

Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced favorable results for the cost-effectiveness of Vicineum based on an independent analysis issued by ICER in its final report published on December 17, 2020.

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 21, 2020.

Janux Therapeutics, today announced a strategic collaboration and license agreement with Merck, known as MSD outside the United States and Canada, to discover, develop and commercialize innovative, next generation T cell engager immunotherapies for the treatment of cancer.

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced plans to host a virtual event and live Q&A session on Tuesday, January 19, 2021 at 8:00 am ET.

CANbridge Pharmaceuticals Inc., a company developing and commercializing innovative drugs to treat rare diseases and targeted cancers, announced that its Investigational New Drug (IND) application for CAN106, a recombinant human monoclonal antibody targeting complement C5 of the complement system, has been approved by the Health Sciences Authority (HSA) in Singapore for the treatment of complement dysregulation diseases

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the European Commission has exercised its option to purchase an additional 80 million doses of mRNA-1273, Moderna’s COVID-19 vaccine candidate, bringing its confirmed order commitment to 160 million doses.

Occlutech, a privately-held company, announced today that the US Food and Drug Administration (FDA) has granted the company a Breakthrough Device designation for its first-in-class, implantable Atrial Flow Regulator (AFR) for Pulmonary Arterial Hypertension (PAH).

Kewaunee Scientific Corporation reported that the Kewaunee International Group was honored by the Confederation of Indian Industry in the category of “Customer Centricity” in a function held at National Conference on Consumer Awareness & Protection in Digital era – The New Normal, Customer Obsession awards ceremony on 15th December 2020 in India.